The liposomal drug delivery systems developed for treatment of COPD

The purpose of this study is to evaluate the newly developed liposomal drug delivery systems in the treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD, is a progressive and a settled disease characterized by airflow limitation in individuals with a genetic predisposition caused by chronic exposure to environmental factors and which can be treated and preventable disease. Inhalation systems are systems for implementing a predetermined amount of active agent to the lungs. Methods for inhalation are classified as metered dose inhaler (MDI), dry powder inhaler (KTI) and the nebulizer. The drug targeting is the selective routing of pharmacological active substance to the effect or absorption area and prepared formula is a particular structure which the active substance is transported with. Liposomes are microscopic vesicles consisting essentially of phospholipits. Liposomes have the ability to carry both oilsoluble and water-soluble molecules at the same time due to its hydrophilic and hydrophobic regions. The increase in the prevalence of asthma and COPD in society, gradually increases the importance of the inhaler therapy.